BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Mthera Pharma Co.\, Ltd. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Mthera Pharma Co.\, Ltd.'s drugs 
 run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06175767-1684@assetmemo.bio
DTSTAMP:20261121T010124Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:MT101-5: Phase 2 readout est. (NCT06175767)
DESCRIPTION:MT101-5\, phase 2\, Parkinson's Disease.\nStudy: A Study to Eva
 luate the Safety\, Tolerability and Efficacy of MT101-5 in Subjects With E
 arly Parkinson's Disease\nEstimated primary completion: January 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/mt101-5#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06175767
URL:https://assetmemo.bio/drug/mt101-5#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
